uropean regulators say that Teva Pharmaceuticals and its Cephalon unit breached antitrust rules by agreeing to delay a cheaper generic version of the Provigil sleep-disorder pill from reaching consumers.

The findings, which are preliminary, refer to the same so-called pay-to-delay arrangement that, two years ago, prompted Teva to pay $1.2 billion to the U.S. Federal Trade Commission to settle allegations that the companies violated antitrust law.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.